Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/agmr/volume-2023/2333767/figures/2333767.fig.007a.svgz" name="2333767.fig.007a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Positive dynamics</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/agmr/volume-2023/2333767/figures/2333767.fig.007b.svgz" name="2333767.fig.007b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Non-negative dynamics</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/agmr/volume-2023/2333767/figures/2333767.fig.007c.svgz" name="2333767.fig.007c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>Negative dynamics</td></tr></table>

<div>Correlations between AR content in serum and faeces and cell-mediated immunity parameters in patients with lung cancer before and after ICI therapy with different dynamics.</div>

Advanced Gut & Microbiome Research

fig7

Figure 7

Figure 7: Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment 